Ovid Therapeutics Inc. (OVID) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ovid Therapeutics Inc., a Delaware corporation, on September 16, 2025, regarding an event that occurred on September 11, 2025. The Company's common stock trades on The Nasdaq Stock Market LLC under the symbol "OVID."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory compliance event rather than financial performance.
Material Changes
The material change reported is the resolution of a listing deficiency. On September 11, 2025, the Company received formal notification from Nasdaq confirming it has regained compliance with Nasdaq Listing Rule 5550(a)(2). This rule requires listed companies to maintain a minimum bid price of at least $1.00 per share. The matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No new risks or contingencies were disclosed in this specific report, other than the prior risk of delisting which has been resolved.
Key Facts for Investor Verification
- Confirm the current trading price of OVID stock remains above the $1.00 minimum bid price threshold.
- Verify the Company's continued compliance with other Nasdaq listing requirements.
- Review recent 10-Q or 10-K filings for the most up-to-date financial position, as this 8-K contains no financial data.